Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
暂无分享,去创建一个
A. Langerak | C. Verhoef | G. Verjans | D. Grünhagen | A. V. D. van der Veldt | K. Heezen | A. Mooyaart | D. Verver | E. Mulder | J. Damman | Sam Tas | Tamana Khemai-Mehraban | Roxane A Wouters
[1] B. Neyns,et al. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells , 2021, Frontiers in Immunology.
[2] M. Ross,et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial , 2021, Nature Medicine.
[3] D. Agnese,et al. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma , 2021, Journal of cutaneous pathology.
[4] P. Ferrucci,et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma , 2021, Cancers.
[5] W. V. van Houdt,et al. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model , 2021, Cancer Immunology, Immunotherapy.
[6] R. Dummer,et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. , 2021, Cancer cell.
[7] T. J,et al. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies , 2021, Oncoimmunology.
[8] C. Sautès-Fridman,et al. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. , 2020, Seminars in immunology.
[9] R. Dummer,et al. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma , 2020, Journal for ImmunoTherapy of Cancer.
[10] L. Cerroni,et al. Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions – a case series , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[11] Dongsheng Xu,et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors , 2020, Biomarker Research.
[12] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.
[13] Y. Zakharia,et al. Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review , 2019, Cancers.
[14] I. Puzanov,et al. Intratumoral Immunotherapy—Update 2019 , 2019, The oncologist.
[15] K. Stamatopoulos,et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS , 2019, Leukemia.
[16] K. Harrington,et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma , 2019, Journal of Immunotherapy for Cancer.
[17] W. V. van Houdt,et al. High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a) , 2019, International journal of cancer.
[18] J. Shiu,et al. The histological spectrum of talimogene laherparepvec (TVEC) injections—Neutrophilic and chronic granulomatous dermatitis , 2018, Journal of cutaneous pathology.
[19] J. Zager,et al. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience , 2018, Annals of Surgical Oncology.
[20] C. Tannenbaum,et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series , 2018, Journal of Immunotherapy for Cancer.
[21] R. Conry,et al. Talimogene laherparepvec: First in class oncolytic virotherapy , 2018, Human vaccines & immunotherapeutics.
[22] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[23] J. Kim,et al. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases , 2018, Journal of cutaneous pathology.
[24] K. Harrington,et al. Oncotargets and Therapy Dovepress , 2022 .
[25] Martin Demko,et al. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data , 2016, Bioinform..
[26] H. Kaufman,et al. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy , 2016, Journal of Immunotherapy for Cancer.
[27] K. Harrington,et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study , 2016, Journal of Immunotherapy for Cancer.
[28] K. Looker,et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012 , 2015, PloS one.
[29] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. E. Schrader,et al. IgH Chain Class Switch Recombination: Mechanism and Regulation , 2014, The Journal of Immunology.
[31] C. Lilley,et al. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma , 2014, Oncolytic virotherapy.
[32] J. Carlson,et al. Cutaneous Vasculitis Update: Neutrophilic Muscular Vessel and Eosinophilic, Granulomatous, and Lymphocytic Vasculitis Syndromes , 2007, The American Journal of dermatopathology.
[33] R. Coombes,et al. A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor , 2006, Clinical Cancer Research.
[34] Guangwu Xu,et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know , 2006, Cell Research.
[35] R. Coffin,et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.
[36] Cather Jc,et al. Herpes simplex virus type 1 infections. , 1998 .